Cytokinetics announces data from phase 2 clinical study of reldesemtiv
Cytokinetics announced data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy. This hypothesis-generating study met its primary objective to determine potential pharmacodynamic effects of reldesemtiv after multiple oral doses in patients with SMA. June 16, 2018